Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Course in the Treatment of Acute Myeloid Leukemia With Venetoclax: The Venetoclax Registry

Next Previous
Trial Profile

Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Course in the Treatment of Acute Myeloid Leukemia With Venetoclax: The Venetoclax Registry

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 09 Jan 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Venetoclax (Primary) ; Cytarabine; Fludarabine; Idarubicin
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms VENreg

    • Most Recent Events

    • 13 Dec 2022 Results (n=118; data cut off date:December 31, 2021 ) assessing to compare FLAVIDA with FLA-IDA as salvage chemotherapy in R/R AML and assess MRD response and overall survival (OS). presented at the 64th American Society of Hematology Annual Meeting and Exposition
    • 17 Jun 2021 Results (n=30; data cut off date: February 9, 2021) assessing the safety and efficacy data of a novel combination therapy consisting of the BCL-2 inhibitor venetoclax with fludarabine, cytarabine, and idarubicin in patients with R/R acute myeloid leukemia, presented at the 26th Congress of the European Haematology Association.
    • 21 Jun 2020 Results (n=42) analyzing the incidence and outcome of TLS in AML patients treated with full-dose VEN without dose ramp-up in combination with non-intensive chemotherapy regimens presented at the 25th Congress of the European Haematology Association
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top